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Acute myeloblastic leukemia (AML) is characterized by
the accumulation of abnormal myeloblasts (mainly
granulocyte or monocyte precursors) in the bone marrow
and blood. Though great progress has been made for
improvement in clinical treatment during the past decades,
only minority with AML achieve long-term survival.
Therefore, further understanding mechanisms of leuke-
mogenesis and exploring novel therapeutic strategies are
still crucial for improving disease outcome. MicroRNA-
100 (miR-100), a small non-coding RNA molecule, has
been reported as a frequent event aberrantly expressed in
patients with AML; however, the molecular basis for this
phenotype and the statuses of its downstream targets have
not yet been elucidated. In the present study, we found
that the expression level of miR-100 in vivo was related to
the stage of the maturation block underlying the subtypes
of myeloid leukemia. In vitro experiments further demon-
strated that miR-100 was required to promote the cell
proliferation of promyelocytic blasts and arrest them
differentiated to granulocyte/monocyte lineages. Signi-
ﬁcantly, we identiﬁed RBSP3, a phosphatase-like tumor
suppressor, as a bona ﬁde target of miR-100 and validated
that RBSP3 was involved in cell differentiation and
survival in AML. Moreover, we revealed a new path-
way that miR-100 regulates G1/S transition and S-phase
entry and blocks the terminal differentiation by targeting
RBSP3, which partly in turn modulates the cell cycle
effectors pRB/E2F1 in AML. These events promoted
cell proliferation and blocked granulocyte/monocyte
differentiation. Our data highlight an important role
of miR-100 in the molecular etiology of AML, and
implicate the potential application of miR-100 in cancer
therapy.
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Acute myeloblastic leukemia (AML) arises from the
differentiation arrest of myeloid precursor and malig-
nant proliferation in the bone marrow (BM) and blood.
It can be divided into different subtypes based on the
cell type and the degree of maturity (Lowenberg et al.,
1999). Although much progress has been achieved in the
clinical treatment of AML in recent decades, only
approximately 40% of patients with AML achieve long-
term survival (Farag et al., 2005; Estey and Do ¨ hner,
2006; Estey, 2007). Therefore, a better understanding of
the mechanisms responsible for leukemogenesis and an
exploration of novel therapeutic strategies are crucial for
achieving an improved outcome.
The differentiation of AML lineages is regulated by a
dynamic interaction between lineage-speciﬁc regulators,
including microRNAs (miRNAs), which have key
roles in hematopoiesis (Chen, 2005; Fontana et al.,
2007; Jongen-Lavrencic et al., 2008; Han et al., 2010).
MiRNAs, a novel class of small non-coding RNAs that
range from 19 to 25 nucleotides in length, can silence
speciﬁc target genes through translational repression or
direct mRNA degradation (Bartel, 2004; Lim et al.,
2005). The deregulated expression of speciﬁc miRNAs
that modulate the expression of oncogenes and tumor
suppressors is associated with the development of
malignancies (Chen, 2005; Esquela-Kerscher and Slack,
2006). Currently, several miRNAs have been reported
as oncogenes or tumor suppressors in leukemia (Fazi
et al., 2005; Fontana et al., 2007; Bousquet et al., 2008;
Garzon et al., 2009; Pigazzi et al., 2009; Han et al., 2010;
Liu et al., 2010). A few reports have described miRNA
expression that is highly regulated according to the
developmental lineage of the cell and restricted miRNA
expression proﬁles during hematopoiesis. For example,
miR-125b-1 arrests myeloid cell differentiation in
myelodysplastic syndrome (MDS) and in AML
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www.nature.com/onc(Bousquet et al., 2008), and miR-223 regulates the
differentiation of human granulopoiesis (Fazi et al.,
2005). MiR-424 stimulates monocyte differentiation via
the translational repression of NFI-A (Rosa et al.,
2007), and a restricted miRNA signature distinguishes
APL blasts from normal promyelocytes (Careccia et al.,
2009). However, the functions of other miRNAs in
leukemia have been minimally explored.
MiR-100 is aberrantly expressed in a number of
cancer cells, including AML cells with a t(15;17)
(Jongen-Lavrencic et al., 2008; Li et al., 2008; Varnholt
et al., 2008; Leite et al., 2009). A few studies have also
reported that miR-100 regulates the expression of
Polo-like kinase 1 in nasopharyngeal cancer, whereas
it targets mTOR in adrenocortical cancer cells and in
clear cell ovarian cancer (Nagaraja et al., 2010; Shi et al.,
2010). These results suggest that miR-100 might func-
tion as a tumor suppressor or as an oncogene in
different cancers. We have previously found that miR-
100 is signiﬁcantly upregulated in AML patients at the
time of diagnosis (Zhang et al., 2009). This ﬁnding raises
the possibility that miR-100 might have an important
role in the development or pathogenesis of AML.
However, the molecular basis for this phenotype has
not been elucidated, and the status of the downstream
targets of miR-100 in AML remains unknown.
In the present study, we explored the functional role
of miR-100 in AML. We found that miR-100 was highly
expressed in AML, particularly in acute granulocytic
leukemia, and the expression levels of miR-100 were
related to the stage of the maturation block underlying
the myeloid leukemia subtypes. In vitro experiments
further demonstrated that miR-100 overexpression in
AML cells inhibited RBSP3 and in turn led to an
increase in the level of phosphorylated pRB and in the
release of E2F1. These events promoted cell prolifera-
tion and blocked granulocyte/monocyte differentiation.
The present results suggest that miR-100 may serve as a
novel therapeutic target in AML.
Results
MiR-100 expression is upregulated in primary AML
Using diagnostic BM samples, we analyzed miR-100
expression in 48 patients with AML, 9 with the AML-
M1 (according to the FAB classiﬁcation) subtype, 7 with
AML-M2, 18 with AML-M3, 4 with AML-M4 and
10 with AML-M5. Five BM samples from healthy
donors were analyzed as controls. The characteristics of
the patients were shown in Table 1. Figure 1a showed
that miR-100 is expressed at low levels in total nucleated
cells from BM of healthy donors. Upregulated miR-100
expression was detected in almost all of the subtypes,
and the expression of miR-100 was much higher in
AML- M1, M2 and M3 (Figure 1a). More interestingly,
miR-100 was detected at the higher levels of expression
in the AML-M1 presenting the immature myeloid
phenotype, and slightly increased its expression in the
myeloblastic AML-M2 subtype and at the highest
levels of expression in primary AML-M3. These results
showed that miR-100 exhibited high expression in
myeloid cells that commit to differentiate to granulocyte
and monocyte cells in normal program while differ-
entiation arrest in AML, strongly implying the relation-
ship of upregulation of miR-100 and myeloid cell’s
differentiation block.
We have also detected the expression of miR-100
precursor in the clinical samples (Figure 1b) and found
that miR-100 precursor is extremely higher in AML-M1,
M2 and M3, consistent with mature miR-100 expres-
sion. These results suggest that aberration of miR-100
expression was not at the processing level.
Upregulation of miR-100 arrests human granulocyte and
monocyte differentiation and promotes cell survival
To investigate the potential role of miR-100 in myeloid
cell differentiation, especially in promyeloid stages,
we ﬁrst examined the expression proﬁles of miR-100
during the differentiation of the myeloid leukemia cell
line HL60 during induction with all-trans retinoic acid
(ATRA) and 1,25-dihydroxy-vitamin D3 (1,25D3),
which can inhibit cell growth and induce granulo-
cyte and monocyte phenotypes, respectively (Supple-
mentary Figures S1 and S2) (Collins et al., 1990; Ji and
Studzinski, 2004). The expression of miR-100 was detec-
ted at 48h and 96h after the treatments. The miR-100
expression level decreased in response to both drugs in a
dose-dependent (Figures 1c and d) and time-dependent
manner (Figures 1e and f). Moreover, miR-100 pre-
cursor expression was determined after 12h and 96h
of ATRA and 1,25D3 treatment by northern blot
(Figure 1g). A reduced expression level of miR-100
Table 1 AML patients’ characteristics




WBC count,  10
9/l 46.3.5 (1.2–671.22)
Less than 10 20 (41.6)
10–50 12 (25.0)
50 or higher 7 (14.5)










Both negative 10 (20.8)
Abbreviations: AML, acute myelogenous leukemia; CR: complete
remission with 3 years clinical follow-up; FAB: French-American-
British classiﬁcation; PML/RARA: promyelocytic leukemia/retinoic
acid receptor alpha; WBC, white blood cell.
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Oncogeneprecursor is similar to that of same as mature miR-100
during both granulocytic and monocytic differentiation,
which suggested that miR-100 negatively regulated
promyeloid cell terminal differentiation.
Next, we examined whether the overexpression of
miR-100 could arrest cell differentiation. HL60 cells
were transfected with the negative control RNA duplex
(denoted miR-NC) or miR-100 mimics, and then treated
with either ATRA or 1,25D3. The miR-NC has been
demonstrated to have minimal sequence identity with
human miRNA (Dharmacon, Lafayette, CO, USA).
Transfection efﬁciency of miR-100 mimics was deter-
mined by qRT–PCR (Supplementary Figure S3A).
As shown in Figures 2a and b, the expression levels
of both CD11b and CD15 increased following ATRA
treatment. Notably, miR-100-transfected cells clearly
displayed low expression levels of the differentiation
markers in comparison with miR-NC-transfected cells
Figure 1 Expression of miR-100 in AML patients and the human leukemia cell line HL60 following induction with all-trans retinoic
acid (ATRA) and 1a, 2,5-dihydroxyvitamin D3 (1,25D3). (a, b) The expression level of mature miR-100 (a) and miR-100 precursor
(b) in AML patients (from AML M1 to M5), respectively, was quantiﬁed by real-time PCR, normalized to the expression of U6 and
presented as the 2
 DDCt value relative to the normal samples. Both mature miR-100 and miR-100 precursor was signiﬁcantly
upregulated in the M1, M2 and M3 subtypes in comparison with the healthy controls, but a low expression level was detected in the
M4, M5 subtypes (**Po0.01). (c, d) MiR-100 expression was detected in HL60 cells after 48h and 96h of treatment with different
concentrations of ATRA (c) and 1,25D3 (d) by qRT–PCR, respectively. (e, f) A time-dependent downregulation of miR-100 in HL60
cells was observed following exposure to 1mM ATRA (e) and 100nM 1,25D3 (f). The asterisks demonstrate statistically signiﬁcant
differences compared with the corresponding vehicle-treated control (CTL) (*Po0.05). (g) MiR-100 precursor expression was
determined at 12h and 96h after treatment of 1mM ATRA or 100nM 1,25D3, respectively, by Northern blot. The value under each
sample indicates the fold change of miR-100 precursor level in ATRA- or 1,25D3-treated cells, relative to that in CTL. A full colour
version of this ﬁgure is available at the Oncogene journal online.
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OncogeneFigure 2 Role of miR-100 in granulocytic/monocytic differentiation and myeloid cell proliferation. (a–d) Transient transfection of
HL60 cells with miR-100 blocked the granulocytic differentiation induced by ATRA. Percentage of CD11b and CD15 positive cells
in HL60 cells 72h after electroporation with H2O or the miRNA duplex as follows: (a)H 2O without ATRA, (b)H 2O with ATRA,
(c, d) miR NC or miR-100 mimics with ATRA. (e–h) Experiments corresponding to a–d but with 1,25D3 treatment and percentage of
CD11b and CD14-positive cells were determined. (i–m) Morphological analysis of HL60 cells at day 4 after electroporation with H2O
or the miRNA duplex as follows: (i)H 2O without ATRA, (j)H 2O with ATRA, (k) miR-NC with ATRA and (l) miR-100 duplex with
ATRA. A representative experiment is shown. (m) Graphic representation of the morphological data corresponding to the mean of
three independent experiments. The number of differentiated granulocytic cells compared with the number of undifferentiated cells
(without ATRA). (n–r) Experiments corresponding to i–m but with 1,25D3 treatment. (s, t) MiR-100 signiﬁcantly promotes cell
proliferation in HL60 (s) and NB4 (t) cells used CCK-8 assay kit. All of the values in the histograms represent the means±s.e.m. of
triplicate determinations.
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Oncogene(Figures 2a–d). In particular, the expression of CD15
was reduced signiﬁcantly. A maturation arrest of mono-
cytic differentiation was also observed. As shown in
Figures 2g and h, the markers of monocytic differen-
tiation CD11b and CD14 were reduced in miR-100-
transfected HL60 cells in response to treatment with
1,25D3 (Figures 2e–h). The differentiation toward
granulocytic/monocytic lineages was further conﬁrmed
based on morphology (Figures 2i–r). These results
indicated that miR-100 overexpression could signiﬁ-
cantly prevent differentiation toward both lineages.
In addition, we assessed whether miR-100 had an
effect on cell proliferation using the CCK-8 assay. As
expected, the proliferation of HL60 cells was stimulated
by the overexpression of miR-100 (Figure 2s, Po0.05 at
48h and Po0.01 from 72h to 96h), and this effect was
time-dependent. However, no clear dose-dependent
effect was detected. Similar results were observed in
NB4 cells (Figure 2t, Po0.01). These data suggested
that miR-100 might function as an oncogene and
contribute to AML progression by blocking myeloid
cell differentiation and promoting proliferation.
MiR-100 targets the phosphatase-like gene RBSP3 via
translational repression
The elucidation of miRNA targets remains a major issue
in functional investigations of miRNAs. Putative targets
of miR-100 were searched using TargetScan (http://
www.targetscan.org/), PICTAR (http://pictar.bio.nyu.
edu/) and miRBase (http://microrna.sanger.ac.uk/
sequences/index.shtml) and 37 potential targets were
predicted. Among the predicted targets, 10 are related to
tumorigenesis and thus were selected for further
experimental validation (Supplementary Table S1 and
part data shown in Supplementary Figure S3). Three
putative targets were experimentally conﬁrmed, includ-
ing RB1 serine phosphates from human chromosome 3
(RBSP3), tribbles homolog 2 (TRIB2) and homeo-
box A1 (HOXA1). Remarkably, RBSP3 demonstrated
the greatest reduction of activity (40%). The predicted
miR-100-binding 30 UTR of RBSP3 is conserved in
humans, mice and rats (Figure 3a), and the interaction
between miR-100 and target mRNA sequences was
further validated using luciferase reporter assays with
a deleted, point and full mutation of putative miR-100
binding sites in the 30 UTR of the RBSP3 gene
(Figures 3b and c).
To conﬁrm that the RBSP3 protein is suppressed by
miR-100, we performed both miR-100 overexpression
and knockdown experiments in HL60 cells and exam-
ined the expression of RBSP3. As shown in Figure 3d,
the level of RBSP3 protein was signiﬁcantly reduced in
HL60 cells that were transfected with the miR-100
mimic, but it was increased in cells that were transfected
with the miR-100 inhibitor (antisense), which transfec-
tion efﬁciency was determined by qRT–PCR (Supple-
mentary Figure S3B). These data indicated that RBSP3
is a bona ﬁde target of miR-100 in myelopoiesis.
To further validate the correlation of miR-100 and
RBSP3 in vivo, we have choosed 17 cases at random to
determine the expression of miR-100 and the protein
levels of RBSP3 in primary patients. Figure 3e showed
that the expression of RBSP3 is extremely low in
AML-M3, and reversely correlated with miR-100 in
AML about 76.5%.
The RBSP3 gene is involved in myeloid cell differentiation
and cell proliferation via the dephosphorylation of RB and
the release of E2F1
RBSP3, which has been previously denoted as HYA22
and CTDSPL, is a recently identiﬁed phosphatase-like
tumor suppressor gene that dephosphorylates the Rb1
serine on Ser-807 and Ser-811 (Kashuba et al., 2004).
A recent study revealed that RBSP3 is involved in the
regulation of cell growth and differentiation, and
frequent mutations in this gene are detected in human
hematopoietic cell lines (Kashuba et al., 2009). How-
ever, the function of RBSP3 in leukemia has not yet
been elucidated.
To explore whether RBSP3 is involved in myeloid cell
differentiation, we ﬁrst determined the expression level
of RBSP3 protein in HL60 cells following induction
with ATRA or 1,25D3. A signiﬁcant increase in RBSP3
protein levels was detected in response to both treatments
(Figures 3f and g). Notably, the expression level of
RBSP3 increased in a dose- and time-dependent manner
(Figure 3h), and this phenomenon correlated negatively
with miR-100 expression (Figures 1c–f). The results
further demonstrated that RBSP3 reversed the effects of
miR-100 and had a role in promyeloid cell differentiation.
To further unravel the function of RBSP3, loss- and
gain-function were performed with RNA interference
and lentivirus construct, respectively, to conﬁrm the role
of this gene in cell differentiation and proliferation.
Among two siRNAs duplexes (siRBSP3-1 or 2),
siRBSP3-2 caused an obvious reduction in both
endogenous mRNA and protein levels in HL60 cells,
which was selected for further study (Figure 4a).
Meanwhile, RBSP3 protein level was increased in
HL60 cells infected by lentivirus–RBSP3 (lv-RBSP3)
compared with lentivirus negative control (lv-NC)
(Figure 4b). As expected, reduced CD11b and CD15
expression levels were detected in siRBSP3-2-transfected
HL60 cells, while increased CD11b and CD15 expres-
sion in lentivirus infected ones in comparison with
the controls following treatment with ATRA (Figures
4c–h). Similarly, CD11b/CD14 inhibition and elevation
was observed in siRBSP3 and lentivirus transducted
cells, respectively, following 1,25D3 treatment (Figures
4i–n). These results suggest that RBSP3 promotes
promyeloid cell differentiation. We further explored
the role of RBSP3 in cell proliferation using the CCK-8
assay. HL60 cells survival gradually increased from 24h
to 96h following transfection with siRBSP3 (Figure 4o),
while suppressed in cells with lentivirus infected
(Figure 4p). These results were similar to that obtained
in the miR-100 studies, which indicates that RBSP3
functions as a suppressor of cell growth in AML.
Previous studies have shown that RBSP3 can
inﬂuence the phosphorylation status of pRB and then
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Oncogenethe release of E2F1. Next, we asked whether RBSP3 has
functional relevance with the reduction of the phos-
phorylated form of pRB protein and blockage of E2F1
in myeloid cells. To address this issue, we transfected
siRBSP3 into HL60 cells and found that the expression
levels of pRB and E2F1 protein increased with the
downregulation of RBSP3, while the amount of total
RB protein remained approximately the same in all of
the treatments (Figure 5a). These data implied that
RBSP3 might have a crucial role in myeloid cell
differentiation toward granulocytic/monocytic lineages
through the pRB–E2F1 pathway.
MiR-100 regulates cell differentiation and survival via its
target RBSP3, which in turn modulates the cell cycle
effector pRB/E2F1 in myeloid cells
As we demonstrated that miR-100 could block differen-
tiation and promote proliferation in AML cells by
Figure 3 MiR-100 directly targets RBSP3, which responds to ATRA and 1,25D induction. (a) Sequences of the predicted miR-100
binding sites in human, mouse and rat genomic regions. Highly conserved nucleotides are shown in blue. (b) Schematic of the luciferase
reporter assay used to validate the interaction between miR-100 and the 30 UTR of RBSP3. Red font indicates the ‘seed’ regions. MRE
RBSP3 30 UTR of wild, deleted, point mutant and full mutant were separately inserted into a psiCheck2 vector downstream from the
Renilla luciferase gene. (c) Repression of luciferase activity due to the interaction between miR-100 and the luciferase constructs. Each
Renilla luciferase reading was normalized to that obtained for the control ﬁreﬂy luciferase. (d) Western blot analysis of the expression
level of RBSP3 following the overexpression of miR-100 mimics or the knockdown of endogenous miR-100 using miR-100 antisense in
HL60 cells. (e) Inverse correlation of expression levels of miR-100 and RBSP3 protein in AML patients (from AML-M1 to M5)
demonstrated by qRT–PCR and western blot. (f, g) Time-course analysis of the induced upregulation of RBSP3 protein in HL60 cells
by 1mM ATRA and 100nM 1,25D3, respectively. RBSP3 protein was gradually upregulated from 4h to 24h after treatment with 100nM
1,25D3.( h) Dose-dependent effect of ATRA and 1,25D3 on RBSP3 protein expression at 96h after treatments. RBSP3 protein
expression increased in a dose-dependent manner following treatment with 0.1uM/1uM ATRA or 1nM/100nM 1,25D3. A full colour
version of this ﬁgure is available at the Oncogene journal online.
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Oncogenerepressing the expression of RBSP3, a bona ﬁde target
of miR-100, and RBSP3 has a crucial role in cellular
differentiation and proliferation in the myeloid lineage
through pRB-E2F1, we hypothesized that miR-100
might contribute to the pathogenesis of AML via the
RBSP3–pRB–E2F1 pathway.
We tested these hypotheses by transfecting miR-100
mimics and the miR-100 inhibitor into HL60 cells. The
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OncogeneFigure 5 MiR-100 targets RBSP3, which modulates the cell cycle effectors pRB/E2F1 and is involved in myeloid cell differentiation
and proliferation. (a) RBSP3 knockdown promoted the phosphorylation of Rb and E2F1. After 72h transfection with siRNA NC or
siRBSP3, cells were collected to analyze the expression of RBSP3, pRb (phosphorylated Rb), Rb (total Rb protein) and E2F1 by
western blotting using b-actin as an internal control. (b) MiR-100 overexpression induced the expression of pRB and E2F1 by
downregulating RBSP3. The cells were collected at the indicated time points for western blot analysis. (c) The knockdown of miR-100
expression results in an upregulation of RBSP3 expression and a downregulation of pRB and E2F1 expression. Cells were collected at
the indicated time points after transfection with miRNA antisense. Protein expression was assessed by western blot analysis. pRb,
phosphorylated Rb; Rb, total Rb protein; b-actin, internal control. (d–g) MiR-100 promoted entry into S-phase of the cell cycle.
(d) The cell cycle phase was analyzed by FACS at 24h after the transfection with H2O in HL60 cells (without nocodazole). (e–g) Cell
cycle phase data in HL60 cells transfected with H2O, miR-NC or miR-100 (with nocodazole). The data correspond to the mean of three
independent experiments (Po0.05). (h) Schematic representation of a pathway modulated by miR-100 in myeloid cells undergoing
differentiation toward granulocytosis/monocytosis and proliferation in AML. MiR-100 overexpression in myeloid cells induced
progression through the G1/S transition and promoted S-phase entry. Thus, miR-100 induced cell proliferation and blocked
promyeloid differentiation by repressing its downstream target RBSP3, which in turn resulted in the phosphorylation of RB and an
accumulation of the downstream cell cycle effector E2F1.
Figure 4 RBSP3 is involved in myeloid cell differentiation and cell proliferation. (a) The qRT–PCR and western blot analysis of the
effects of different items of siRBSP3. *Po0.05. (b) Western blot analysis of the infection efﬁciency of Lentivirus RBSP3. (c–h) CD11b/
CD15 expression following transfection with H2O, siRBSP3 or lv-RBSP3 by FACS (Po0.05): (c, d)H 2O without or with ATRA,
(e, f) miR NC or miR-100 with ATRA and (g, h) lv-NC and lv-RBSP3 with ATRA.A representative experiment is shown.
(i–n) Corresponding FACS experiments with c–h but the cells were treated with 1,25D3. A representative experiment is shown.
(o) The transfection of HL60 cells with siRBSP3 signiﬁcantly promoted myeloid cell proliferation. Cell viability was determined using
the CCK-8 assay. The time points after transfection with H2O, siRNA NC, siRBSP3, miR-NC or miR-100 are indicated.
(p) Corresponding FACS experiments with (o) but the cells were transfected with H2O, anti-miR-NC, anti-miR-100, lv-NC or
lv-RBSP3. *Po0.05. A full colour version of this ﬁgure is available at the Oncogene journal online.
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Oncogeneoverexpression of miR-100 resulted in the downregula-
tion of RBSP3 protein at different time points. How-
ever, the expression levels of the pRB and E2F1 proteins
increased, and the total levels of RB protein remained
the same at all time points (Figure 5b). Meanwhile, the
results for the protein expression levels of RBSP3, pRB
and E2F1 in anti-miR-100 transfectants were opposite
with those obtained for miR-100, excluding the ﬁndings
determined for RB, which remained unchanged in any
case (Figure 5c). These results support the hypothesis
that miR-100 regulates the RBSP3–pRB–E2F1 pathway
at the level of translation.
Because the downstream target E2F1 is a master cell
cycle regulator, we also analyzed the cell cycle by FACS
to identify S activation via the overexpression of miR-
100. The transfected cells were synchronized by treat-
ment with nocodazole, which depolymerizes the micro-
tubules and blocks the cell cycle at G2/M-phase. After
24h of synchronization, cells were determined by FACS
analysis. Results showed that a substantial increase in
the G2 population was observed, while most of the
miR-100-transfectants could escape this block and enter
S-phase (Figures 5d–g). These results further support
the hypothesis that miR-100 activates the downstream
effector E2F1 and promotes S-phase entry.
Collectively, these results demonstrate that miR-100
contributes to AML pathogenesis by targeting the
RBSP3–pRB–E2F1 pathway to affect cell proliferation
and differentiation.
Discussion
The inhibition of hematopoietic precursor differentia-
tion is a characteristic of different types of AML.
Several studies have shown that genome-wide gene
expression patterns are highly related to different
subtypes of AML, and have provided a better under-
standing of the underlying biology of this disease.
Recently, miRNAs have emerged as important cellular
regulators that mediate cellular development and
differentiation. Previous studies have shown that miR-
100 is aberrantly expressed in several types of leukemia,
including AML with t(15;17) or inv(16) (Dixon-McIver
et al., 2008; Li et al., 2008). In the present study, we
found that miR-100 inhibits differentiation of myeloid
cells toward granulocyte/monocyte lineages. The under-
lying molecular pathway responsible for the effects of
miR-100 in myeloid leukemia cell survival and differ-
entiation might control the G1 to S phase transition by
repressing RBSP3, which modulates the RB-E2F1
signaling pathway. We propose that a high expression
level of miR-100 may disrupt the cell cycle control,
promote cell proliferation, block cell differentiation
and consequently facilitate the development of cancers
such as AML. These effects characterize a new role for
miR-100.
Two observations conﬁrm our hypothesis. First, we
observed a differential expression pattern of miR-100 in
different subtypes of AML, and interestingly, we found
that miR-100 precursor and mature were highly
expressed in AML-M1, M2 and M3. In contrast, lower
expression levels were noted in other AML subtypes,
such as the M4 and M5 phenotypes, in which the
cellular programs for monocytic phenotype are already
partially established. Actually, our results indicated that
miR-100 could block myeloid cell differentiation and
promote cell proliferation during both granulocytic
and monocytic differentiation. Next, we investigated
the molecular pathway that might be controlled by miR-
100. Several putative targets were predicted and notably,
RBSP3 was validated. Importantly, expression of
RBSP3 protein is most inverse correlation with miR-
100 in AML clinical samples. RBSP3 is an important
candidate tumor suppressor gene located at 3p21.3
(Kashuba et al., 2004; Anedchenko et al., 2008; Sinha
et al., 2008; Ghosh et al., 2010; Senchenko et al., 2010);
however, the involvement of RBSP3 in the regulation of
cell differentiation and growth in myeloid cells has not
yet been studied. We demonstrated that RBSP3 protein
expression was elevated during ATRA- and 1,25D3-
induced promyeloid cell differentiation toward granu-
locytic and monocytic lineages, respectively. Moreover,
loss- and gain-function were introduced to demonstrate
that RBSP3 is associated with cell differentiation and
proliferation with RNA interference and lentivirus
constructs. Expression proﬁles of CD11b/CD15 or
CD11b/CD14 have been detected either downregulated
or upregulated in knockdown or overexpressed-RBSP3
cells, respectively, which were similar to the results
obtained in ectopic miR-100 expression. These results
indicate that the activation of the phosphatase RBSP3
protein may be a common step that is required for
granulocytic/monocytic differentiation.
Previous studies have also reported that RBSP3
removes the phosphate group from serine 807 and 811
in its substrate, phosphorylated RB (pRB), and thereby,
it induces the formation of the RB-E2F1 complex
(Ghosh et al., 2010). The ‘RB’ pathway has a critical
role in both cell physiology and tumorigenic transfor-
mation via distinct molecular mechanisms, in particular,
through the mediation of G1 progression and the G1/S
transition (Chen et al., 1989; Strauss et al., 1995;
Weinberg, 1995; Bartek et al., 1996, 1997; Hall and
Peters, 1996; Sherr, 1996). In the present study, over-
expression experiments showed that enforced expression
of miR-100 could inhibit RBSP3, upregulate pRB and
release E2F1. The release of E2F1 blocks the differ-
entiation induced by ATRA or 1,25D3 and promotes the
survival of HL60 cells. The knockdown experiment
revealed that the loss of miR-100 provided the opposite
result. These ﬁndings indicate that the aberrant expres-
sion of pRB-E2F1 and RBSP3 during differentiation
and proliferation might be correlated with the expres-
sion level of miR-100. In AML cells, a high expression
level of miR-100 represses the expression of RBSP3,
which in turn leads to increased pRB phosphorylation
and E2F1 release. The release of E2F1 might provide
a G1/S transition checkpoint and activate progression
through S-phase, thus arresting promyeloid cell differen-
tiation, inducing proliferation and leading to AML
progression. The schematic representation of the role of
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differentiation and proliferation in AML is shown in
Figure 5h.
To date, an increasing number of studies have revealed
that miRNAs have an important role in AML. For
example, Garzon et al. (2009) found that miR-29b has a
tumor suppressor function and affects the survival of
AML cells by targeting MCL-1 and upregulating BIM
and PDCD4 transcripts. Liu et al. (2010) discovered the
Sp1/NFkB/HDAC/miR-29b regulatory network in KIT-
driven AML. Pigazzi et al. (2009) demonstrated that
miR-34b targets the cyclic AMP-responsive element-
binding network in AML . Recently, Pulikkan et al.
(2010) reported that E2F1 and miR-223 comprise an
autoregulatory negative feedback loop in AML. E2F1 is
a cell cycle regulator, inhibits granulopoiesis and induces
myeloid cell cycle progression (Strom et al., 1998). E2F1
is regulated directly by miR-330 in prostate cancer cells
(Lee et al., 2009), by miR-149* in neuroblastoma cells
and HeLa cells (Lin et al., 2010) and by miRNA-331-3p
in gastric cancer cells (Guo et al., 2010). In addition,
1,25D3 induces monocytic phenotype differentiation in
HL-60 human myeloid leukemia cells, and this process is
mediated by Akt through Raf/MEK/ERK MAPK
signaling (Wang et al., 2009). To our knowledge, this is
the ﬁrst report to clearly demonstrate the mechanism by
which miR-100 inhibits RBSP3 during granulopoiesis
and monocytic differentiation. MiR-100 targets RBSP3
and regulates its expression in AML, which reveals a new
post-transcriptional mechanism of regulation in the
myeloid lineage. In addition, another kinase mTOR
was also validated as a target of miR-100 in AML in this
study, suggesting that miR-100 may involve in a
complicated network. The manipulation of miR-100
could be diagnostically and therapeutically relevant to
treat AML subtypes.
Materials and methods
Patients, sample collection and therapeutic methods
A total of 48 AML patients and ﬁve healthy donors from
the First and Second Afﬁliated Hospital of Sun Yat-sen
University were enrolled in the study. The demographics for all
of the patients are presented (see Table 1). The BM from
patients and healthy donors was collected via a BM puncture
at the time of diagnosis or during the follow-up process.
Written informed consent to perform the biological studies
was obtained from all of the patients, and the study was
approved by the Ethics Committee of the afﬁliated hospitals
at Sun Yat-sen University.
RNA analysis
Total RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. The following oligonucleotides were used as probes for
mature miR-100: RT primer, 50-GTCGTATCCAGTGCAG
GGTCCGAGGTATTCGCACTGGATACGACCACAAG-30;
PCR forward primer, 50-GCGGC AACCCGTAGATCCGAA-30;
PCR reverse primer, 50-GTGCAGGGTCCGAGGT-30. Endo-
genous U6 small nuclear RNA was detected as an internal
control using the following oligonucleotides: forward primer,
50-CGCTTCGGCAGCACATATAC-30; reverse primer, 50-TT
CACGAATTTGCGTGTCAT-30. MiR-100 precursor primers
were designed as describe previously (Jiang et al., 2005). PCR
forward primer: 50-AACCCGTAGATCCGAACTTG-30; PCR
reverse primer: 50-TACCTATAGATACAAGCTTGTGCG-30.
U6 small nuclear RNA forwards primer: 50-CTCGCTTCGG
CAGCACA-30; reversed primer: 50-AACGCTTCACGAATT
TGCGT-30. The miR-100 precursor and U6 reverse transcrip-
tion primers were used as the reverse primer. Where indicated,
both miRNA mature and precursor quantiﬁcation was
performed by real-time PCR with an ABI PRISM 7900
Sequence Detection System (Applied Biosystems, Foster City,
CA, USA). The delta Ct values were normalized to those
obtained from the ampliﬁcation of endogenous U6 small
nuclear RNA. All of the reactions were performed in triplicate.
Real-time PCR was performed to quantify the mRNA
expression using ExTaq SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s instruc-
tions. The following oligonucleotides were used for RBSP3:
forward primer, 50-CGCTTCGGCAGCACATATAC-30, re-
verse primer 50-TTCACGAATTTGCGTGTCAT-30. The
RBSP3 transcript was detected using the TaqMan oligonu-
cleotides HS 00325656.m1 (Applied Biosystems). The delta Ct
values were normalized to those obtained from the ampliﬁca-
tion of endogenous b-actin mRNA using the Quantitect
Primer Assay (Qiagen, Guangzhou, China). All of the
reactions were performed in triplicate.
Northern blot
HL60 cells were treated with 1mM ATRA and 100nM 1,25D3 at
12h and 96h, respectively. Total RNA was extracted with
Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. In all, 80mg of total RNA was separated on a
15% denaturing polyacrylamide gel, transferred to positively
charged membrane (PerkinElmer, Boston, MA, USA) using
Trans-Blot semi-dry eletrophoretic transfer cell (Bio-Rad)
and then immobilized by UV crosslinking at 354nm for
4min each face and baking at 801C under vaccum for 50min.
The membranes were pre-hybridized and then hybridized
at 421C for 24h to a g-
32P-labeled DNA oligonucleotide that
was complementary to the sequence of miR-100 precursor
(probe sequence: 50-CTTGTGCGGACTAATACCACAAGT
TCGGATCTACGGGTT-30 and U6: 50-CCATGCTAATCT
TCTCTGTATC-30) thereafter, the membranes were washed
and exposed to a Storage Phosphor Screen, which was subse-
quently read with STORM 820 Phosphor Imager (Amersham
Bioscience, Sunyvale, CA, USA).
Vector constructs
The 30-untranslated terminal region (UTR) segment com-
prising 59bp of the 30 UTR of RBSP3 was synthesized by
Sangon (Shanghai, China) and inserted into the psiCheck-
control vector (Promega, Madison, WI, USA) for the miRNA
functional analysis. The RBSP3 deleted/psiCheck-RBSP3-
deleted vector, which spanned 8bp of the site of perfect
complementarily to miR-RBSP3, was generated by PCR
deletion. The RBSP3 point mutated/psiCheck-RBSP3-point
mutated vector was mutated at 1, 3, 4, 6 and 8 point, and the
RBSP3 full mutated/psiCheck-RBSP3-full mutated vector was
full mutation of the perfect complementarily site, respectively.
Wild type, deleted insertions, point mutation and full mutation
were conﬁrmed by DNA sequencing.
Statistical analysis
The Fisher’s exact test, t-test and w
2-test were used to compare
baseline characteristics and the average miRNA expression
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normal donors. Other data are expressed as the mean±s.e.m.
of at least three independent experiments. The differences
between groups were analyzed using the Student’s t-test when
only two groups were compared or one-way analysis of
variance when more than two groups were compared. Po0.05
was considered statistically signiﬁcant.
Cell lines and transient transfection
Two human acute myeloid leukemic cell lines, HL60 and NB4,
were cultured in RPMI 1640 medium (Invitrogen). The human
embryonic kidney cell line HEK-293T was grown in Dulbec-
co’s modiﬁed Eagle’s medium (Invitrogen). Both cultures were
supplemented with 10% fetal bovine serum (fetal bovine
serum, Australia) and sodium pyruvate and cultured at 371C
in a humidiﬁed atmosphere consisting of 5% CO2.
For the luciferase reporter assay, HEK-293T cells were
grown in 24-well plates at a density of 1 10
5 cells per well in
0.5ml of complete growth medium. The cells were transfected
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol.
The following were purchased from GenePharma (Shanghai,
China): miR-100 mimics; miR-NC, a miRNA negative control;
miR-100 antisense with a sequence complementary to mature
miR-100; and miR antisense NC, a negative control for
miR-100 antisense. The small interfering RNAs (siRNA)
against human RBSP3 (GenBank Access. No. NM_005808)
transcripts (denoted siRBSP3) and the negative control RNA
duplex (denoted SiRNA NC) were purchased from Guangzhou
Ribo-Bio Co., Ltd. (Guangzhou, China).
HL60 and NB4 cells were grown in 24-well plates
containing a density of 1 10
6 cells per well in 0.5ml of
complete growth medium. The cells were transfected with the
small molecular RNAs mentioned above using the Neon
Transfection System (Invitrogen). The electroporation condi-
tions were as follows: 1350V, 35ms width and one pulse for
HL60 cells; 1400V, 10ms width and three pulses for NB4 cells.
Luciferase reporter assay
Transient transfections were performed in HEK-293T cells with
100nM miR-100 mimics or miR-100 negative control; 0.1mgo f
psiCheck control or psiCheck-RBSP3; or psiCheck-RBSP3-
deleted, or psiCHECK-RBSP3-point mutated vector or psi-
CHECK-RBSP3-full mutated vector containing the ﬁreﬂy
luciferase reporter vector and 0.1mg of the control vector
containing Renilla luciferase (pRL-TK) (Promega). HL60 cells
were transfected by electroporation with 100nM miR-100
negative control, 2.5mg of the psiCheck-control or psiCheck-
RBSP3 or psiCheck-RBSP3-deleted or psiCheck-RBSP3-point
mutated vector, or psiCheck-RBSP3-full mutated vector con-
taining ﬁreﬂy luciferase report vector and 2.5mg of the control
vector containing Renilla luciferase, pRL-TK (Promega). Fireﬂy
and Renilla luciferase activities were measured consecutively at
24h after transfection using Dual-luciferase assays (Promega)
according to the manufacturer’s instructions.
Cell proliferation assays
Cell proliferation was determined using the Cell Counting
Kit-8 (CCK-8) as described previously (Hamamoto et al.,
2004). Cells in a 24-well plate were transfected by electropora-
tion with 100nM miR-100 mimics, 200nM miR-100 antisense,
100nM siRBSP3 and the corresponding doses of miR NC,
miR antisense NC and siRNA NC, respectively. After trans-
fection, 1 10
4 cells per well were plated in 96-well plates, and
the CCK-8 assay (Dojindo Molecular Technologies, Shanghai,
China) was conducted after 24h, 48h, 72h and 96h.
Evaluation of myeloid differentiation
Lentivirus RBSP3-infected cells and various cells transfected
with 100nM miR-100, 100nM siRBSP3 and their negative
controls by electroporation after 24h, were treated with 1mM
ATRA (Sigma-Aldrich, Shanghai, China) and 10nM 1,25-
dihydroxy-vitamin D3 (1,25D3) (Sigma-Aldrich), respectively.
Both granulocytic and monocytic differentiation was evaluated
at day 4 after ATRA or 1,25D3 induction based on the cell
morphology on Wright-Giemsa-stained slides. In all, 300 cells
were counted to evaluate morphology. The expression of CD11b
and CD15 for granulocytic differentiation and the expression of
CD11b and CD14 for monocytic differentiation were detected
on day 3 after induction by ﬂuorescence activated cell sorter
(FACS) analysis. For the FACS assay, the cells were
stained with the following anti-human monoclonal antibodies:
CD14-PE (eBioscience, San Diego, CA, USA), CD15-perCP
(eBioscience), CD11b-APC (Invitrogen), which were measured
using a FACSCaliber (BD Bioscience, San Jose, CA, USA). The
data were analyzed using FACSDiva software (BD Biosciences).
A minimum of 10000 events were collected for each sample.
Western blot assay
The cells were treated as indicated in the ﬁgures and lysed in
RIPA buffer (Pierce, Rockford, IL, USA) with protease
and phosphatase inhibitors (Roche, Beijing, China). The
protein was separated in a 10% polyacrylamide gel and
transferred to a methanol-activated PVDF membrane (Milli-
pore, Beijing, China). The membrane was blocked for 2h in
Tris-buffered saline Tween-20 (TBST) containing 2% bovine
serum albumin and then probed with polyclonal rabbit
anti-RBSP3 (Novus Biologicals, Littleton, CO, USA), anti-
phospho-Rb (Ser 807/811) (Cell Signaling Technology, Bos-
ton, MA, USA), monoclonal mouse anti-Rb (4H1) (Cell
Signaling Technology), anti-E2F1 (clones KH20 and KH95,
Upstate Millipore, Guangzhou, China) and polyclonal rabbit
anti-glyceraldehyde-3-phosphate dehydrogenase antibodies
(Proteintech Technology, Manchester, UK) or anti-b-actin anti-
body (Cell Signaling Technology) overnight at 41C. After a 1h
incubation with anti-mouse (Pierce) or anti-rabbit (Sigma-
Aldrich) HRP-conjugated secondary antibody, the protein level
was detected using a luminal reagent (Millipore).
Cell cycle assay
The cells were transfected with H2O (denoted as mock), miR
NC or miR-100 mimics by electroporation and plated in a
24-well plate. Nocodazole (100ng/ml) was added to the cells
24h after transfection. The cells were cultured for an additional
24h, collected and incubated with NP40/propidium iodide (PI)
buffer and 0.5mL of RNase (30mg/ml) for 30min at 371C
before FACS analysis. PI-negative living cells were gated for the
cell cycle analysis.
Lentiviral construction and infection
To overexpress RBSP3 in cells, lentiviral vector was cons-
tructed from. Brieﬂy, full-length complementary DNA of
RBSP3 (831bp) were inserted to pLVX-PGK-IRES–ZsGreen
lentiviral control vectors. pLVX-PGK–hRBSP3–IRES–ZsGreen
or pLVX-PGK–IRES–ZsGreen and three packaged plasmids
co-transfected into HEK-293T cells. Supernatant were harvested
at 24 and 48h after transfection passed through 0.45mma n d
concentrated. In all, 25ml lentivirus-RBSP3(lv-RBSP3) and 5ml
lentivirus negative control (lv-NC) containing medium was
mixed with equal volume 8mg/ml polybrene (hexadimethrine
bromide, Sigma, St Louis, MO, USA), and then used to infect
HL60 cells. After 24h, target cells were washed twice with PBS
and cultured in fresh medium until further analysis.
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